816 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
BMY Bristol-Myers Squibb Company $61.3 $100.03B N/A
Article Searches
Celgene (CELG) Presents Data on Pipeline Candidates at ASCO http://www.zacks.com/stock/news/424905/celgene-celg-presents-data-on-pipeline-candidates-at-asco?cid=CS-ZC-FT-424905 Jun 05, 2019 - Celgene (CELG) presents data on myelofibrosis candidate from a phase II study and an oncology candidate at ASCO.
10 Jaw-Dropping Numbers About Cancer Drug Development -- and What They Mean for Investors https://www.fool.com/investing/2019/06/05/10-jaw-dropping-numbers-about-cancer-drug-developm.aspx?source=iedfolrf0000001 Jun 05, 2019 - There's more good news with the fight against cancer than you might think.
Merck's Antibiotic Zerbaxa Gets FDA Nod for New Indication http://www.zacks.com/stock/news/424586/mercks-antibiotic-zerbaxa-gets-fda-nod-for-new-indication?cid=CS-ZC-FT-424586 Jun 04, 2019 - Merck (MRK) gets FDA approval for antibacterial medicine, Zerbaxa for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP)
Bristol-Myers (BMY) Presents Multiple Data on Opdivo at ASCO http://www.zacks.com/stock/news/424416/bristol-myers-bmy-presents-multiple-data-on-opdivo-at-asco?cid=CS-ZC-FT-424416 Jun 04, 2019 - Bristol-Myers (BMY) announces data from multiple studies on immuno-oncology drug, Opdivo, at ASCO.
Why Cancer-Fighting Stocks & ETFs Are Soaring http://www.zacks.com/stock/news/424108/why-cancer-fighting-stocks-etfs-are-soaring?cid=CS-ZC-FT-424108 Jun 03, 2019 - The cancer immunotherapy ETF is soaring today as some of its holdings presented very promising results at the ASCO conference. Find out more on the podcast.
Novartis (NVS) Announces Various Data Presentations at ASCO http://www.zacks.com/stock/news/424089/novartis-nvs-announces-various-data-presentations-at-asco?cid=CS-ZC-FT-424089 Jun 03, 2019 - Novartis (NVS) announces a number of data presentations at the ASCO 2019 annual meeting.
AstraZeneca's Imfinzi Shows Long-Term Benefits in Lung Cancer http://www.zacks.com/stock/news/423951/astrazenecas-imfinzi-shows-long-term-benefits-in-lung-cancer?cid=CS-ZC-FT-423951 Jun 03, 2019 - AstraZeneca (AZN) presents follow-up data on Imfinzi from late-stage PACIFIC study evaluating it in lung cancer patients.
Roche Presents Positive Data on Xolair & Updates From ASCO http://www.zacks.com/stock/news/423876/roche-presents-positive-data-on-xolair-updates-from-asco?cid=CS-ZC-FT-423876 Jun 03, 2019 - Roche (RHHBY) reports positive data from late-stage studies on allergic asthma drug, Xolair, for a new indication, and additional results on Tecentriq and Avastin combo at ASCO.
Merck's Keytruda Improves 5-Year Survival in Lung Cancer http://www.zacks.com/stock/news/423872/mercks-keytruda-improves-5-year-survival-in-lung-cancer?cid=CS-ZC-FT-423872 Jun 03, 2019 - Merck (MRK) presents longest follow-up data for Keytruda in advance lung cancer at ASCO 2019. The five-year overall survival rates in the Keytruda arm are better than historical rates
Gilead Presents Data on CAR T Cell Therapy Candidate at ASCO http://www.zacks.com/stock/news/423909/gilead-presents-data-on-car-t-cell-therapy-candidate-at-asco?cid=CS-ZC-FT-423909 Jun 03, 2019 - Gilead (GILD) presents data from a phase I study on experimental CAR T cell therapy, KTE-X19, at ASCO and announces collaboration with Humanigen.

Pages: 12345678...82

<<<Page 3>